Provider Briefing: Bonjesta Availability in 2026

If your patients have been reporting difficulty filling their Bonjesta prescriptions, you're hearing a story that's become increasingly common across OB/GYN practices. While Bonjesta (Doxylamine Succinate 20 mg / Pyridoxine Hydrochloride 20 mg extended-release) remains on the market and is not in a formal FDA-listed shortage, real-world access challenges persist for many patients.

This article provides an updated clinical and logistical overview for providers prescribing Bonjesta in 2026, including the current supply picture, insurance landscape, cost considerations, and practical tools to help your patients access their medication.

Timeline: How We Got Here

Bonjesta received FDA approval in November 2016 as an extended-release formulation of the Doxylamine/Pyridoxine combination previously available only as Diclegis (10 mg/10 mg delayed-release). It was designed to offer a more convenient dosing regimen — a maximum of 2 tablets daily versus up to 4 for Diclegis — while providing both immediate and sustained symptom relief through its dual-layer tablet design.

Since launch, Bonjesta has faced several headwinds affecting patient access:

• 2016-2019: Initial market entry with limited formulary adoption; many payers classified it as non-preferred or excluded it outright
• 2019-2022: Generic Diclegis approval expanded lower-cost alternatives, further reducing payer willingness to cover brand-name Bonjesta
• 2023-present: Duchesnay USA introduced the Bonjesta At Home mail-order program and copay assistance to address access barriers

Throughout this period, the supply issue has never been one of manufacturing capacity but rather of last-mile pharmacy access driven by economics and formulary decisions.

Prescribing Implications

Clinical Considerations

Bonjesta's extended-release formulation offers a genuine clinical advantage for patients who need sustained NVP control with fewer daily doses. The dual-layer tablet provides immediate-release Doxylamine 10 mg / Pyridoxine 10 mg plus delayed-release Doxylamine 10 mg / Pyridoxine 10 mg, creating a pharmacokinetic profile distinct from Diclegis.

When prescribing Bonjesta, consider the following:

• First-line therapy: ACOG guidelines recommend vitamin B6 with or without Doxylamine as first-line pharmacotherapy for NVP. Bonjesta is a branded formulation of this first-line combination.
• Step therapy requirements: Most payers require documented trial and failure of OTC Doxylamine/B6 or generic Diclegis before authorizing Bonjesta. Document these trials clearly in the patient chart.
• Patient counseling: Advise patients to take Bonjesta on an empty stomach, swallow tablets whole (no crushing or splitting), and take it daily rather than as needed for consistent relief. The most common side effect is drowsiness.

For complete prescribing details, refer to the Bonjesta clinical overview and mechanism of action guide.

Drug Interactions and Safety

Bonjesta is contraindicated with concurrent MAOI use or within 14 days of MAOI discontinuation. Concurrent use with other CNS depressants (including opioids, benzodiazepines, and alcohol) can cause additive sedation. Review the full drug interaction profile before prescribing.

Current Availability Picture

The current availability landscape for Bonjesta can be summarized as follows:

• FDA shortage status: Not listed on FDA Drug Shortage Database
• Manufacturing: Duchesnay USA continues active production and distribution
• Wholesale availability: Available through major wholesalers (McKesson, Cardinal Health, AmerisourceBergen)
• Retail pharmacy stocking: Inconsistent — many chain pharmacies do not maintain regular stock due to low fill volume per location
• Generic status: No generic Bonjesta available; generic Diclegis is available

The practical reality is that patients may need to check multiple pharmacies or use alternative access pathways (discussed below) to fill their prescriptions.

Cost and Access Landscape

Cost remains a significant barrier for Bonjesta patients:

• Average retail price: $480-$830 for 30 tablets
• GoodRx coupon price: As low as $180 for 30 tablets
• Manufacturer copay card: Commercially insured patients may pay as little as $35-$45 via the eVoucherRx program
• Bonjesta At Home: $60 for 30 tablets or $99 for 60 tablets with free home delivery (for uninsured/underinsured patients)

For comparison, generic Diclegis costs approximately $30-$60 for 60 tablets, and OTC Doxylamine + B6 costs under $15.

Insurance Coverage Notes

The insurance landscape for Bonjesta remains challenging:

• UnitedHealthcare typically excludes both Bonjesta and Diclegis from coverage
• Most commercial plans require prior authorization with step therapy (trial of OTC B6/Doxylamine → generic Diclegis → Bonjesta)
• Medicaid coverage varies by state
• Some plans will cover Bonjesta if the provider submits documentation of treatment failure with alternatives

Tools and Resources for Your Practice

Several resources can help streamline Bonjesta access for your patients:

Medfinder for Providers

Medfinder offers a provider-facing tool that allows your practice to help patients locate pharmacies with Bonjesta in stock. This can be integrated into your patient education workflow to reduce callbacks from patients unable to fill prescriptions.

Manufacturer Programs

• Bonjesta CoPay Savings Card: Available at bonjesta.com/bonjesta-savings — for commercially insured patients
• Bonjesta At Home: Mail-order program for cash-pay patients ($60-$99) — call 1-800-250-5195
• eVoucherRx electronic coupon: Paperless system that works at participating pharmacies

Prior Authorization Support

Duchesnay USA offers prior authorization support through their provider hotline. When submitting PAs, include:

• Documentation of failed OTC Doxylamine + B6 trial
• Documentation of failed generic Diclegis trial (if applicable)
• Clinical rationale for extended-release formulation (e.g., improved adherence, symptom control with fewer daily doses)

Alternative Prescribing Considerations

When Bonjesta access proves difficult for a patient, consider these evidence-based alternatives:

1. Generic Diclegis (Doxylamine/Pyridoxine 10 mg/10 mg delayed-release): Most accessible first-line option; generic widely available
2. OTC Doxylamine + vitamin B6: Recommend Unisom SleepTabs (Doxylamine) — specify this by name to avoid confusion with Diphenhydramine-containing products
3. Ondansetron (Zofran): Off-label for NVP; reserve for moderate-to-severe cases unresponsive to Doxylamine/B6
4. Promethazine: Off-label; effective but more sedating; available as tablets and suppositories
5. Metoclopramide: Off-label; consider for severe NVP or hyperemesis gravidarum

Looking Ahead

Several developments may affect Bonjesta access in the coming months:

• Generic Bonjesta: No generic application is currently approved, but this remains a possibility that would significantly improve access and affordability
• Formulary reviews: Annual payer formulary updates may affect coverage; encourage patients to check their plan's drug list at the start of each benefit year
• Digital tools: Platforms like Medfinder continue to expand, making it easier for both providers and patients to navigate medication availability

Final Thoughts

Bonjesta remains a clinically valuable option for NVP management, but real-world access challenges require proactive management from the prescribing team. By understanding the insurance landscape, leveraging manufacturer programs, and using availability tools like Medfinder, you can help your patients access this medication more efficiently.

For a practical workflow guide on helping patients find Bonjesta, see our companion article: How to Help Your Patients Find Bonjesta in Stock. For cost-saving strategies to share with patients, see How to Help Patients Save Money on Bonjesta.